ADC Therapeutics SA
NYSE:ADCT
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.7235
5.29
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ADCT stock under the Base Case scenario is 5.3 USD. Compared to the current market price of 1.99 USD, ADC Therapeutics SA is Undervalued by 62%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
ADC Therapeutics SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ADCT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
ADC Therapeutics SA
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
ADC Therapeutics SA
Balance Sheet Decomposition
ADC Therapeutics SA
Current Assets | 333m |
Cash & Short-Term Investments | 274.3m |
Receivables | 24m |
Other Current Assets | 34.7m |
Non-Current Assets | 16.1m |
PP&E | 14.9m |
Other Non-Current Assets | 1.2m |
Current Liabilities | 67.7m |
Accounts Payable | 14.4m |
Accrued Liabilities | 33.4m |
Other Current Liabilities | 19.9m |
Non-Current Liabilities | 453.3m |
Long-Term Debt | 436.8m |
Other Non-Current Liabilities | 16.5m |
Earnings Waterfall
ADC Therapeutics SA
Revenue
|
123.5m
USD
|
Cost of Revenue
|
-7.1m
USD
|
Gross Profit
|
116.4m
USD
|
Operating Expenses
|
-380.6m
USD
|
Operating Income
|
-264.2m
USD
|
Other Expenses
|
-103m
USD
|
Net Income
|
-367.2m
USD
|
Free Cash Flow Analysis
ADC Therapeutics SA
USD | |
Free Cash Flow | USD |
ADCT Profitability Score
Profitability Due Diligence
ADC Therapeutics SA's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
ADC Therapeutics SA's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
ADCT Solvency Score
Solvency Due Diligence
ADC Therapeutics SA's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
ADC Therapeutics SA's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADCT Price Targets Summary
ADC Therapeutics SA
According to Wall Street analysts, the average 1-year price target for ADCT is 9.18 USD with a low forecast of 8.08 USD and a high forecast of 10.5 USD.
Dividends
Current shareholder yield for ADCT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ADCT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
Contact
IPO
Employees
Officers
The intrinsic value of one ADCT stock under the Base Case scenario is 5.3 USD.
Compared to the current market price of 1.99 USD, ADC Therapeutics SA is Undervalued by 62%.